布拉迪酵母菌
医学
内科学
幽门螺杆菌
荟萃分析
随机对照试验
置信区间
相对风险
科克伦图书馆
不利影响
养生
胃肠病学
益生菌
遗传学
细菌
生物
作者
Hania Szajewska,Andrea Horvath,Maciej Kołodziej
摘要
Summary Background Unsatisfactory Helicobacter pylori eradication rates and therapy‐associated side effects remain a problem. Aim To update our 2010 meta‐analysis on the effects of Saccharomyces boulardii as supplementation to a standard eradication regimen on H. pylori eradication rates and therapy‐associated side effects. Methods The Cochrane Library, MEDLINE and EMBASE databases were searched from July 2010 (end date of last search) to February 2015, with no language restrictions, for randomised controlled trials (RCTs); additional references were obtained from reviewed articles. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines. Results Eleven RCTs (2200 participants, among them 330 children) met the inclusion criteria. Of the 853 patients in the S. boulardii group, 679 (80%, 95% CI 77–82) experienced eradication compared with 608 of the 855 patients (71%, 95% CI 68–74) in the control group [relative risk (RR) 1.11, 95% confidence interval (CI) 1.06–1.17; moderate quality evidence]. S. boulardii compared with control reduced the risk of overall H. pylori therapy‐related adverse effects (RR 0.44, 95% CI 0.31–0.64; moderate quality evidence), particularly of diarrhoea (RR 0.51, 95% CI 0.42–0.62; high quality evidence) and nausea [RR 0.6, 95% CI 0.44–0.83 (moderate quality of evidence)]. Conclusions In the populations studied, the effectiveness of standard triple therapy was unsatisfactory. The addition of S. boulardii significantly increased the eradication rate, but it was still below the desired level of success. Saccharomyces boulardii significantly decreased some therapy‐related side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI